Form 4: ALX Oncology Holdings Inc. Director Exercises Options and Sells Shares

Jaume Pons, President & CSO of ALX Oncology Holdings Inc., exercised stock options and sold 20,000 shares of common stock on June 4, 2024.

Summary

• Jaume Pons, President & CSO of ALX Oncology Holdings Inc., executed transactions involving the company's stock on June 4, 2024.
• Pons exercised an employee stock option to acquire 20,000 shares of common stock at a price of $0.99 per share.
• Simultaneously, Pons sold 20,000 shares of common stock at a weighted average price of $8.4326 per share, with individual sales ranging from $8.17 to $8.87.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 6, 2023.
• Following these transactions, Pons directly owns 604,205 shares of ALX Oncology Holdings Inc. common stock and holds options for 164,433 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy, mitigating potential negative interpretations. The exercise of options is a positive sign, while the sale is a neutral event in this context.

Positives

• The exercise of options demonstrates the executive's belief in the company's long-term potential, as they are willing to invest at the exercise price.
• The use of a pre-arranged 10b5-1 trading plan suggests that the sales were planned and not based on any inside information.

Negatives

• The sale of shares by a high-ranking executive could be perceived negatively by some investors, potentially signaling a lack of confidence, although the 10b5-1 plan mitigates this concern.

Risks

• Executive stock sales can sometimes create short-term downward pressure on the stock price.
• There is always a risk that investors may misinterpret the reasons for the stock sale, even with the disclosure of the 10b5-1 trading plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and are usually not a cause for concern, especially when conducted under pre-arranged trading plans. Investors often monitor these transactions for insights into management's perspective on the company's value and future prospects.

Comparison to Industry Standards

• Executive compensation packages often include stock options to align management's interests with those of shareholders.
• Rule 10b5-1 trading plans are a standard practice for corporate insiders to sell shares without raising concerns about insider trading.
• The size of the transaction (20,000 shares) is relatively small compared to the total outstanding shares of ALX Oncology Holdings Inc., suggesting it is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the potential for short-term price fluctuations.
• Employees may view the executive's stock activity as a reflection of the company's prospects, but the 10b5-1 plan should reassure them that the sales are pre-planned.

Key Dates